COVID shot sales: Pfizer lowers outlook, Moderna maintains guidance

Pfizer slashed the guidance for revenues of Paxlovid by $7 billion, which includes a $4.2 billion non-cash revenue reversal for the return of the nearly 8 million treatment courses from the U.S. government inventory.